Faculty Opinions recommendation of Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial.

2013 ◽  
Author(s):  
Bo Carlberg ◽  
Mattias Brunström
Keyword(s):  
Blood Pressure ◽  
Endothelial Function ◽  
Diuretic Therapy ◽  
Double Blind ◽  
Renin Angiotensin Aldosterone System ◽  
Double Blind Placebo ◽  
Differential Effects ◽  
Renin Angiotensin

scholarly journals Blueberries Improve Endothelial Function, but Not Blood Pressure, in Adults with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Nutrients ◽  
2015 ◽  
Vol 7 (6) ◽  
pp. 4107-4123 ◽  
Author(s):  
April Stull ◽  
Katherine Cash ◽  
Catherine Champagne ◽  
Alok Gupta ◽  
Raymond Boston ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Endothelial Function ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effect of captopril on blood pressure and renin-angiotensin-aldosterone system in hypertensive patients on hemodialysis.

1982 ◽  
Vol 137 (1) ◽  
pp. 21-31 ◽  
Author(s):  
HIROSHI KANEDA ◽  
TOYOAKI MURATA ◽  
JUN MATSUMOTO ◽  
TAKAKICHI MAETA ◽  
KOZO SHITOMI ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Renin Angiotensin Aldosterone System ◽  
Hypertensive Patients ◽  
Renin Angiotensin

scholarly journals Tactics of antihypertensive therapy during COVID-19 pandemic

2021 ◽  
Vol 93 (9) ◽  
pp. 1125-1131
Author(s):  
Valery I. Podzolkov ◽  
Anna Е. Bragina ◽  
Yulia N. Rodionova ◽  
Galina I. Bragina ◽  
Ekaterina E. Bykova
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Diseases ◽  
Arterial Hypertension ◽  
Ace Inhibitor ◽  
Fixed Combination ◽  
Significant Risk ◽  
Effective Control ◽  
Combination Drug ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin

Results of foreign and Russian studies indicate a higher mortality rate of patients with concomitant cardiovascular diseases (CVD) due to the new coronavirus infection COVID-19. It has been proven that arterial hypertension, as one of the significant risk factors for the development of concomitant cardiovascular diseases, is associated with a more severe prognosis of COVID-19. This article presents the results of modern studies and large meta-analyzes of necessity and safety of the use of blockers of the renin-angiotensin-aldosterone system in patients with arterial hypertension and COVID-19. The data of studies show that an angiotensin-converting enzyme inhibitor (ACE inhibitor) and a thiazide-like diuretic is a pathogenetically rational combination. It realizes various ways of lowering blood pressure by reducing the activity of the renin-angiotensin-aldosterone system, which is achieved by using an ACE inhibitor, and natriuresis due to diuretics. As an example, a highly effective fixed combination of drugs is considered, characterized by good tolerance, which consists of an ACE inhibitor lisinopril and a thiazide-like diuretic indapamide of prolonged action. The authors expressed the opinion that the appointment of the fixed combination drug Diroton Plus (Gedeon Richter) will contribute to effective control of blood pressure and organoprotection in conditions of increased thrombogenic and prooxidative potential, characteristic of COVID-19 both in the acute stage and within the post-COVID Syndrome.

Sign in / Sign up

Export Citation Format

Share Document